Skip to main content


The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new

On September 12, Sanofi announced that it withdrew the FDA application for its once-daily GLP-1 agonist lixisenatide... Continue Reading »

Are all carbs created equal? Adam learns why 30 grams of carbs is NOT always 30 grams of carbs… Continue Reading »

A whole new approach to treating type 2 diabetes at diagnosis, a new type of metformin, and the benefit of adding a GLP-1 agonist to insulin. Continue Reading »

At ADA this year, type 2 drugs for type 1 diabetes show lots of promise. Plus, the latest exciting data on the Medtronic Veo and hypoglycemia. Continue Reading »

TrialNet is bringing their services online, making it easier for... Continue Reading »

In May, Lexicon announced its results of LX4211, an SGLT-1/SGLT-2 inhibitor. The phase 2 trial finished its open-... Continue Reading »